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Abstract
Background:  Previous research has shown that plasma creatine levels are influenced by
extracellular concentrations of insulin and glucose as well as by the intracellular creatine
concentration. However, the form of creatine administered does not appear to have any effect
although specific data on this is lacking. This study examined whether the administration of three
different forms of creatine had different effects on plasma creatine concentrations and
pharmacokinetics.
Methods: Six healthy subjects (three female and three male subjects) participated in the study.
Each subject was assigned to ingest a single dose of isomolar amounts of creatine (4.4 g) in the form
of creatine monohydrate (CrM), tri-creatine citrate (CrC), or creatine pyruvate (CrPyr) using a
balanced cross-over design. Plasma concentration curves, determined over eight hours after
ingestion, were subject to pharmacokinetic analysis and primary derived data were analyzed by
repeated measures ANOVA.
Results: Mean peak concentrations and area under the curve (AUC) were significantly higher with
CrPyr (17 and 14%, respectively) in comparison to CrM and CrC. Mean peak concentration and
AUC were not significantly different between CrM and CrC. Despite the higher peak
concentration with CrPyr there was no difference between the estimated velocity constants of
absorption (ka) or elimination (kel) between the three treatments. There was no effect of
treatment with CrPyr on the plasma pyruvate concentration.
Conclusion: The findings suggest that different forms of creatine result in slightly altered kinetics
of plasma creatine absorption following ingestion of isomolar (with respect to creatine) doses of
CrM, CrC and CrPyr although differences in ka could not be detected due to the small number of
blood samples taken during the absorption phase. Characteristically this resulted in higher plasma
concentrations of creatine with CrPyr. Differences in bioavailability are thought to be unlikely since
absorption of CrM is already close to 100%. The small differences in kinetics are unlikely to have
any effect on muscle creatine elevation during periods of creatine loading.
Published: 12 November 2007
Journal of the International Society of Sports Nutrition 2007, 4:17 doi:10.1186/1550-2783-4-
17
Received: 28 September 2007
Accepted: 12 November 2007
This article is available from: http://www.jissn.com/content/4/1/17
© 2007 Jäger et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of the International Society of Sports Nutrition 2007, 4:17 http://www.jissn.com/content/4/1/17
Page 2 of 5
(page number not for citation purposes)
Background
Creatine supplementation has been reported to increase
muscle creatine and phosphorylcreatine content by 5 to
30% [1]. However, significant intra-subject variability has
been reported in regards to the magnitude that creatine
stores and performance are affected [1-3]. Initial evidence
reported by Chanutin [4] and recently confirmed by Del-
dicque et al. [5] indicates that intestinal absorption of cre-
atine supplied as the monohydrate is close to 100%.
The aim of this pilot study was to compare the effects of
ingesting isomolar amounts of creatine (4.4 g) in the form
of the monohydrate (5 g), tri-creatine citrate (6.7 g) and
creatine pyruvate (7.3 g) on creatine concentrations in
plasma. The study was prompted by the fact that salts of
creatine are more quickly taken up into solution than the
monohydrate, and thus could offer advantages over the
monohydrate. The inclusion of the small amounts of
pyruvate and citrate were thought unlikely to influence
creatine absorption and uptake, although initial studies
with 25 g pyruvate plus 75 g dihydroxyacetone have indi-
cated an ergogenic effect of pyruvate supplementation
through a proposed stimulation of glucose uptake by
muscle [6]. However, no blood samples were taken in that
study to measure plasma pyruvate levels during the period
of oral supplementation [6,7]. Smaller doses of calcium
pyruvate [6–10 g/d], on the other hand, showed mixed
results in clinical trials [8-10]. Acute calcium pyruvate
supplementation of 7 g, 15 g or 25 g did not result in any
significant elevation of blood pyruvate levels [11] and
consumption of 7 g/d for 7 days did not result in
improved aerobic endurance in well-trained athletes
[11,12].
Methods
Subjects
Three females and three males participated in this pilot
study. All subjects in this investigation participated in a
familiarization session. During the familiarization ses-
sion, subjects were informed as to the experimental proce-
dures, completed a personal/medical history form,
creatine supplementation history form and signed
informed consent statements in adherence with the
human subject's guidelines of the American College of
Sports Medicine. The study was approved by the Ethical
Review Committee of the University of Chichester. Sub-
ject characteristics are presented in table 1. No subject in
this trial was a vegetarian with all subjects reportedly con-
suming meat in their daily diet.
Supplementation Protocol
The study used a cross-over design. Each subject received
the three treatments using a latin-square design on three
different days, with 7 days allowed between each treat-
ment. Treatments comprised:
A: 5 g Creatine monohydrate (CrM) dissolved in 450 ml
of water (control)
B: 6.7 g Tri-creatine citrate (CrC) dissolved in 450 ml of
water (isomolar with respect to creatine to A and C)
C: 7.3 g Creatine pyruvate (CrPyr) dissolved in 450 ml of
water (isomolar with respect to creatine to A and B).
The creatine monohydrate (Creapure™) contains 88% w/
w creatine, creatine pyruvate (Creapure™Pyruvate) con-
tains 60% w/w creatine and 40% w/w pyruvate, and, tri-
creatine citrate (Creapure™Citrate) contains 65% w/w cre-
atine. All three were obtained from Degussa AG (Trost-
berg, Germany) and contained <100 ppm creatinine,
whilst dicyandiamide and dihyrdotriazine levels and pol-
ymeric pyruvates in CrPyr were not detectable by HPLC.
Procedures
Two ml blood samples were collected into tubes contain-
ing lithium heparin through an antecubital vein, centri-
fuged and plasma was harvested and stored frozen until
analysed. Plasma (500 μl) was extracted with 15 μl of 70%
w/w PCA and supernatants after centrifugation were neu-
tralised with a minimum volume of 2N KHCO3at 4°C.
One hundred and sixty one blood samples, from an
intended 162, were collected. Data for from the missing
sample (subject 1, treatment C, 2 hours) were estimated
from the two adjacent points assuming an exponential
decrease between 1.5 to 3 hours. Creatine in plasma
extracts was analysed photometrically by following the
oxidation of NADH at 340 nm in the presence of creatine
kinase, pyruvate kinase and lactate dehydrogenase [13].
Pyruvate was analysed using a similar assay but with the
addition of lactate dehydrogenase only.
Pharmacokinetics
Using a Marquardt algorithm, all kinetics were fitted with
the following equation:
C = (FD/V*(ka/(ka-kel)) * (exp(-kel*t) - exp(-ka*t)))
Where:
Table 1: Subjects characteristics
No. Sex Age (years) Weight (kg) Height (m)
1 M 21 84 1.82
2 M 29 87 1.82
3 M 22 78 1.86
4 F 55 70 1.58
5 F 51 65 1.62
6 F 35 68 1.65Journal of the International Society of Sports Nutrition 2007, 4:17 http://www.jissn.com/content/4/1/17
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C is the plasma creatine concentration minus the basal
concentration (μM)
if C ≤ 0, then data were removed
F is the bioavailability
D is the dose (5 g or 38.17 mmol)
V is the volume of distribution
ka is the velocity constant of absorption (first order, h-1)
kel is the velocity constant of elimination (first order, h-1)
t is the time (h)
No weight was applied to data (weight = 1) and the initial
parameters values were estimated using a Simplex algo-
rithm. This equation corresponds to a one-open compart-
mental model. The area under the curve (AUC) from zero
to infinity was estimated by non compartmental model
Statistical Analysis
Results are shown as means together with standard devia-
tion. Primary and derived variables were analysed by
repeated measures ANOVA. Where a significant effect of
treatment was indicated, data were further compared
using a Bonferroni post-hoc test. The threshold for signif-
icance was set at p < 0.05.
Results
Mean (SD) plasma concentrations following the three
treatments are shown in table 2 and the mean curves are
depicted in figure 1. One hour after the ingestion, the
plasma creatine concentration was higher with CrPyr than
with CrC (p = 0.024, table 2). The difference between
means was larger when CrPyr and CrM were compared,
but in this last case the signification threshold was not
reached (p = 0.089).
Peak concentrations were always the highest after inges-
tion of CrPyr. Mean peak concentrations were 1.17 fold
higher with CrPyr compared to CrC (p = 0.010) and 1.29
fold higher than with CrM, but again missing the thresh-
old of significance (p = 0.075, table 3). The time at which
the peak concentrations were reached (Tmax) was unaf-
fected by the form of creatine ingested as well as the veloc-
ity constants of absorption (ka) and elimination (ke)
(table 3). The mean half-life of elimination was 30 ± 11.6
min. AUC values with CrPyr were also the highest in all
subjects. Mean AUC with CrPyr was 1.14 fold higher com-
pared to CrC although the difference did not reach the
threshold of significance (P = 0.069).
There was no effect of treatments on the plasma pyruvate
concentrations (figure 2).
Discussion
Although creatine is widely used as a dietary supplement,
only a few studies describe data relevant to its pharmacok-
inetics [1,5,14-19]. After ingestion of a single low dose,
the time-course of the changes in plasma concentration is
generally accepted to follow a one-open compartment
model with first-order absorption and elimination con-
stants [20]. The present results support this model.
All treatments at all doses resulted in substantial increases
in plasma creatine which if repeated could be expected to
lead to enhancement of the creatine content in muscle
[1,2]. However, some differences were apparent in the
dynamics of plasma creatine following ingestion of iso-
molar (with respect to creatine) doses of CrM, CrC and
CrPyr. Characteristically this resulted in higher plasma
Table 2: Mean (SD) plasma creatine concentration over 8 hours following ingestion of isomolar amounts of creatine (4.4 g) in the form 
of creatine monohydrate (CrM), tri-creatine citrate (CrC), or creatine pyruvate (CrPyr). Means within each time-row differing 
significantly are denoted by the letters a to c.
Time (h) CrM (a) CrC (b) CrPyr (c) ANOVA P value
Mean SD Mean SD Mean SD
0 4 0 . 5 2 5 . 55 6 . 53 6 . 7 4 4 2 8 N S
0.5 488.6 185.7 551.1 191.3 637 207.2 NS
1 761.9 107.7 855.3 c 165.1 972.2 a 184.1 0.015
1.5 660.8 159.2 771.8 289.3 875.7 310.9 0.012
2 557 162.1 624.2 263.1 681.7 299.4 NS
3 362.5 174.4 400.1 235.7 431.5 228.5 NS
4 247.8 134.8 276 169.3 298 176.3 NS
6 142.7 87.3 189.1 120.2 178.5 110.3 NS
8 103.4 64.5 123.1 83.6 122.9 83.7 NSJournal of the International Society of Sports Nutrition 2007, 4:17 http://www.jissn.com/content/4/1/17
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concentrations of creatine with CrPyr. This may suggest
that faster absorption or slower elimination of creatine
when supplied as CrPyr although this was not evident
from the estimates of ka and kel. Faster absorption of cre-
atine could, for instance occur, as a result of an increase in
metabolisable substrate (i.e. pyruvate or citrate) for use by
enterocytes. It is likely that the small change in ka was
missing due to the small number of blood samples taken
during the absorption phase, namely 3–4 samples. Higher
plasma concentrations could also indicate suppression of
uptake by muscle, possibly through the lowering of insu-
lin in the circulation or due to changes in plasma pH as a
result of the metabolism of pyruvate and citrate supplied,
but this is not supported by the kel values which were cal-
culated over a larger number of data points. The higher
plasma concentration with CrPyr is unlikely to have been
due to greater bioavailability, since the bioavailability of
CrM is known to be close to 100% [4,5]. Differences in
muscular creatine levels during and after supplementa-
tion would be needed to allow a difference in muscular
performance. It is questionable if the small differences
observed in the plasma concentrations with the three
treatments would have any effect on the increase in creat-
ine in muscle. However, this would need to be confirmed
by direct measurement.
The inability to detect any change in the plasma pyruvate
concentration is attributed to the rapid clearance and
metabolism of this by the liver; although decarboxylation
in the stomach and intestine and/or elimination through
the urine or faeces [10] are also possibilities.
Conclusion
The findings suggest that different forms of creatine result
in slightly altered kinetics of plasma creatine absorption
following ingestion of isomolar (with respect to creatine)
doses of CrM, CrC and CrPyr although differences in ka
could not be detected due to the small number of blood
samples taken during the absorption phase. Characteristi-
cally this resulted in higher plasma concentrations of cre-
atine with CrPyr. Differences in bioavailability are
thought to be unlikely since absorption of CrM is already
close to 100%.
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Table 3: Mean (SD) peak plasma concentration (Crmax, mM), time to peak concentration (Tmax, h), area under the plasma 
concentration curve (AUC, mM.h), velocity constant of absorption (ka, h-1) and velocity constant of elimination (ke, h-1) following 
ingestion of isomolar amounts of creatine (4.4 g) in the form of creatine monohydrate (CrM), tri-creatine citrate (CrC), or creatine 
pyruvate (CrPyr). Means differing significantly are denoted by the letters a to c.
CrM (a) CrC (b) CrPyr (c) ANOVA P 
value
Mean SD Mean SD Mean SD
Crmax 751 32.9 837 c 71.5 968 a 82.3 0.008
Tmax 1.5 c 0.13 1.2 0.1 1.1 a 0.08 0.002
AUC 2384 376.5 2627 506.8 2985 540.6 0.023
ka 1.26 0.214 1.39 0.551 1.31 0.324 NS
kel 0.73 0.344 0.66 0.279 0.72 0.279 NS
Mean plasma creatine concentration over 8 hours following  ingestion of 4.4 g of Creatine in the form of creatine mono- hydrate (CrM), tri-creatine citrate (CrC), or creatine pyru- vate (CrPyr) Figure 1
Mean plasma creatine concentration over 8 hours following 
ingestion of 4.4 g of Creatine in the form of creatine mono-
hydrate (CrM), tri-creatine citrate (CrC), or creatine pyru-
vate (CrPyr). Dispersions and statistical significances are 
given in table 2.
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Mean plasma pyruvate concentrations during 8 hours follow- ing ingestion of creatine pyruvate (CrPyr, 7.3 g), creatine  monohydrate (CrM, 5 g) or tri-creatine citrate (CrC, 6.7 g) Figure 2
Mean plasma pyruvate concentrations during 8 hours follow-
ing ingestion of creatine pyruvate (CrPyr, 7.3 g), creatine 
monohydrate (CrM, 5 g) or tri-creatine citrate (CrC, 6.7 g).
 